ANF_HUMAN
ID ANF_HUMAN Reviewed; 151 AA.
AC P01160; Q13766; Q5JZE1;
DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT 11-DEC-2019, sequence version 2.
DT 03-AUG-2022, entry version 218.
DE RecName: Full=Natriuretic peptides A {ECO:0000305};
DE AltName: Full=Atrial natriuretic factor prohormone {ECO:0000303|PubMed:6542248};
DE Short=proANF {ECO:0000303|PubMed:6542248};
DE AltName: Full=Atrial natriuretic peptide prohormone {ECO:0000303|PubMed:22291141};
DE Short=preproANP {ECO:0000303|PubMed:22291141};
DE Short=proANP {ECO:0000305};
DE AltName: Full=Atriopeptigen {ECO:0000303|PubMed:3158606};
DE AltName: Full=Cardiodilatin {ECO:0000303|PubMed:6547996};
DE Short=CDD {ECO:0000303|PubMed:6547996};
DE AltName: Full=preproCDD-ANF {ECO:0000303|PubMed:6547996};
DE Contains:
DE RecName: Full=Long-acting natriuretic peptide {ECO:0000303|PubMed:8653797};
DE Short=LANP {ECO:0000303|PubMed:8653797};
DE AltName: Full=Long-acting natriuretic hormone {ECO:0000305};
DE Short=LANH {ECO:0000305};
DE AltName: Full=Pro atrial natriuretic factor 1-30 {ECO:0000303|PubMed:2162527};
DE Short=proANF 1-30 {ECO:0000303|PubMed:2162527};
DE AltName: Full=Pro atrial natriuretic peptide 1-30 {ECO:0000305};
DE Short=proANP 1-30 {ECO:0000305};
DE Contains:
DE RecName: Full=Vessel dilator {ECO:0000303|PubMed:8653797};
DE Short=VSDL {ECO:0000303|PubMed:8653797};
DE AltName: Full=Pro atrial natriuretic factor 31-67 {ECO:0000303|PubMed:2162527};
DE Short=proANF 31-67 {ECO:0000303|PubMed:2162527};
DE AltName: Full=Pro atrial natriuretic peptide 31-67 {ECO:0000305};
DE Short=proANP 31-67 {ECO:0000305};
DE Contains:
DE RecName: Full=Kaliuretic peptide {ECO:0000303|PubMed:8653797};
DE Short=KP {ECO:0000303|PubMed:8653797};
DE AltName: Full=Pro atrial natriuretic factor 79-98 {ECO:0000303|PubMed:8087923};
DE Short=proANF 79-98 {ECO:0000303|PubMed:8087923};
DE AltName: Full=Pro atrial natriuretic peptide 79-98 {ECO:0000305};
DE Short=proANP 79-98 {ECO:0000305};
DE Contains:
DE RecName: Full=Urodilatin {ECO:0000303|PubMed:2972874};
DE Short=URO {ECO:0000303|PubMed:8853410};
DE AltName: Full=CDD 95-126 {ECO:0000303|PubMed:2972874};
DE AltName: Full=CDD-ANP (95-126) {ECO:0000303|PubMed:8351194};
DE AltName: Full=Pro atrial natriuretic peptide 95-126 {ECO:0000303|PubMed:2528951};
DE Short=proANP 95-126 {ECO:0000303|PubMed:2528951};
DE Contains:
DE RecName: Full=Auriculin-C {ECO:0000305};
DE AltName: Full=Atrial natriuretic factor 1-33 {ECO:0000250|UniProtKB:P01161};
DE Short=ANF 1-33 {ECO:0000250|UniProtKB:P01161};
DE Contains:
DE RecName: Full=Auriculin-D {ECO:0000305};
DE AltName: Full=Atrial natriuretic factor 3-33 {ECO:0000250|UniProtKB:P01161};
DE Short=ANF 3-33 {ECO:0000250|UniProtKB:P01161};
DE Contains:
DE RecName: Full=Atrial natriuretic peptide {ECO:0000303|PubMed:6203042};
DE Short=ANP {ECO:0000303|PubMed:6203042};
DE AltName: Full=Alpha-atrial natriuretic peptide {ECO:0000303|PubMed:3838202};
DE AltName: Full=Alpha-hANP {ECO:0000303|PubMed:3838202};
DE AltName: Full=Atrial natriuretic factor {ECO:0000303|PubMed:2162527};
DE Short=ANF {ECO:0000303|PubMed:2162527};
DE AltName: Full=CDD-ANF {ECO:0000303|PubMed:6203042};
DE AltName: Full=CDD-ANP (99-126) {ECO:0000303|PubMed:8853410};
DE AltName: Full=Cardionatrin {ECO:0000250|UniProtKB:P01161};
DE AltName: Full=Pro atrial natriuretic factor 99-126 {ECO:0000303|PubMed:2162527};
DE Short=proANF 99-126 {ECO:0000303|PubMed:2162527};
DE Contains:
DE RecName: Full=Auriculin-B {ECO:0000305};
DE AltName: Full=Atrial natriuretic factor 8-33 {ECO:0000250|UniProtKB:P01161};
DE Short=ANF 8-33 {ECO:0000250|UniProtKB:P01161};
DE Contains:
DE RecName: Full=Auriculin-A {ECO:0000250|UniProtKB:P01161};
DE Contains:
DE RecName: Full=Atriopeptin-1 {ECO:0000250|UniProtKB:P01161};
DE AltName: Full=Atriopeptin I {ECO:0000250|UniProtKB:P01161};
DE Contains:
DE RecName: Full=Atriopeptin-2 {ECO:0000250|UniProtKB:P01161};
DE AltName: Full=Atriopeptin II {ECO:0000250|UniProtKB:P01161};
DE Contains:
DE RecName: Full=Atriopeptin-3 {ECO:0000250|UniProtKB:P01161};
DE AltName: Full=Atriopeptin III {ECO:0000250|UniProtKB:P01161};
DE Flags: Precursor;
GN Name=NPPA; Synonyms=ANP, PND;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RX PubMed=6203042; DOI=10.1038/309724a0;
RA Oikawa S., Imai M., Ueno A., Tanaka S., Noguchi T., Nakazato H.,
RA Kangawa K., Fukuda A., Matsuo H.;
RT "Cloning and sequence analysis of cDNA encoding a precursor for human
RT atrial natriuretic polypeptide.";
RL Nature 309:724-726(1984).
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA].
RX PubMed=6547996; DOI=10.1038/310699a0;
RA Nakayama K., Ohkubo H., Hirose T., Inayama S., Nakanishi S.;
RT "mRNA sequence for human cardiodilatin-atrial natriuretic factor precursor
RT and regulation of precursor mRNA in rat atria.";
RL Nature 310:699-701(1984).
RN [3]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX PubMed=6095118; DOI=10.1038/312654a0;
RA Nemer M., Chamberland M., Sirois D., Argentin S., Drouin J., Dixon R.A.F.,
RA Zivin R.A., Condra J.H.;
RT "Gene structure of human cardiac hormone precursor, pronatriodilatin.";
RL Nature 312:654-656(1984).
RN [4]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX PubMed=6095119; DOI=10.1038/312656a0;
RA Greenberg B.D., Bencen G.H., Seilhamer J.J., Lewicki J.A., Fiddes J.C.;
RT "Nucleotide sequence of the gene encoding human atrial natriuretic factor
RT precursor.";
RL Nature 312:656-658(1984).
RN [5]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX PubMed=6542248; DOI=10.1126/science.6542248;
RA Seidman C.E., Bloch K.D., Klein K.A., Smith J.A., Seidman J.G.;
RT "Nucleotide sequences of the human and mouse atrial natriuretic factor
RT genes.";
RL Science 226:1206-1209(1984).
RN [6]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX PubMed=3158606; DOI=10.1161/01.hyp.7.3_pt_2.i31;
RA Seidman C.E., Bloch K.D., Zisfein J., Smit J., Haber E., Homcy C.,
RA Duby A.D., Choi E., Graham R.M., Seidman J.G.;
RT "Molecular studies of the atrial natriuretic factor gene.";
RL Hypertension 7:I31-I34(1985).
RN [7]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG NHLBI resequencing and genotyping service (RS&G);
RL Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN [8]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX PubMed=16710414; DOI=10.1038/nature04727;
RA Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT "The DNA sequence and biological annotation of human chromosome 1.";
RL Nature 441:315-321(2006).
RN [9]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Prostate;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [10]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-75.
RX PubMed=6097248; DOI=10.1016/0006-291x(84)90609-0;
RA Maki M., Parmentier M., Inagami T.;
RT "Cloning of genomic DNA for human atrial natriuretic factor.";
RL Biochem. Biophys. Res. Commun. 125:797-802(1984).
RN [11]
RP NUCLEOTIDE SEQUENCE [MRNA] OF 118-151, AND VARIANT ARG-ARG-151 EXT.
RX PubMed=6238331; DOI=10.1073/pnas.81.20.6325;
RA Zivin R.A., Condra J.H., Dixon R.A.F., Seidah N.G., Chretien M., Nemer M.,
RA Chamberland M., Drouin J.;
RT "Molecular cloning and characterization of DNA sequences encoding rat and
RT human atrial natriuretic factors.";
RL Proc. Natl. Acad. Sci. U.S.A. 81:6325-6329(1984).
RN [12]
RP PROTEIN SEQUENCE OF 124-151.
RX PubMed=6230082; DOI=10.1016/0006-291x(84)91077-5;
RA Kangawa K., Matsuo H.;
RT "Purification and complete amino acid sequence of alpha-human atrial
RT natriuretic polypeptide (alpha-hANP).";
RL Biochem. Biophys. Res. Commun. 118:131-139(1984).
RN [13]
RP PROTEIN SEQUENCE OF 26-151, SUBUNIT (ATRIAL NATRIURETIC PEPTIDE), AND
RP DISULFIDE BOND.
RC TISSUE=Heart atrium {ECO:0000303|PubMed:3838202};
RX PubMed=3838202; DOI=10.1038/313397a0;
RA Kangawa K., Fukuda A., Matsuo H.;
RT "Structural identification of beta- and gamma-human atrial natriuretic
RT polypeptides.";
RL Nature 313:397-400(1985).
RN [14]
RP PROTEIN SEQUENCE OF 120-151, SYNTHESIS (URODILATIN), SUBCELLULAR LOCATION
RP (URODILATIN AND ATRIAL NATRIURETIC PEPTIDE), TISSUE SPECIFICITY
RP (URODILATIN), AND PROTEOLYTIC PROCESSING (URODILATIN).
RC TISSUE=Urine {ECO:0000303|PubMed:2972874};
RX PubMed=2972874; DOI=10.1007/bf01726570;
RA Schulz-Knappe P., Forssmann K., Herbst F., Hock D., Pipkorn R.,
RA Forssmann W.G.;
RT "Isolation and structural analysis of 'urodilatin', a new peptide of the
RT cardiodilatin-(ANP)-family, extracted from human urine.";
RL J. Mol. Med. 66:752-759(1988).
RN [15]
RP PROTEIN SEQUENCE OF 124-151.
RX PubMed=1826098; DOI=10.1111/j.1432-1033.1991.tb15815.x;
RA Vanneste Y., Michel A., Deschodt-Lanckman M.;
RT "Hydrolysis of intact and Cys-Phe-cleaved human atrial natriuretic peptide
RT in vitro by human tissue kallikrein.";
RL Eur. J. Biochem. 196:281-286(1991).
RN [16]
RP FUNCTION (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL DILATOR; KALIURETIC
RP PEPTIDE AND ATRIAL NATRIURETIC PEPTIDE).
RX PubMed=2825692; DOI=10.1016/s0006-291x(87)80307-8;
RA Vesely D.L., Norris J.S., Walters J.M., Jespersen R.R., Baeyens D.A.;
RT "Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate
RT the aorta.";
RL Biochem. Biophys. Res. Commun. 148:1540-1548(1987).
RN [17]
RP PROTEOLYTIC PROCESSING BY MME (ATRIAL NATRIURETIC FACTOR), AND CLEAVAGE
RP SITE.
RX PubMed=2972276; DOI=10.1042/bj2540531;
RA Vanneste Y., Michel A., Dimaline R., Najdovski T., Deschodt-Lanckman M.;
RT "Hydrolysis of alpha-human atrial natriuretic peptide in vitro by human
RT kidney membranes and purified endopeptidase-24.11. Evidence for a novel
RT cleavage site.";
RL Biochem. J. 254:531-537(1988).
RN [18]
RP FUNCTION (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL DILATOR AND ATRIAL
RP NATRIURETIC PEPTIDE), SUBCELLULAR LOCATION (LONG-ACTING NATRIURETIC
RP PEPTIDE; VESSEL DILATOR AND ATRIAL NATRIURETIC PEPTIDE), AND PROTEOLYTIC
RP PROCESSING.
RX PubMed=2532366; DOI=10.3181/00379727-192-42990;
RA Vesely D.L., Norsk P., Winters C.J., Rico D.M., Sallman A.L., Epstein M.;
RT "Increased release of the N-terminal and C-terminal portions of the
RT prohormone of atrial natriuretic factor during immersion-induced central
RT hypervolemia in normal humans.";
RL Proc. Soc. Exp. Biol. Med. 192:230-235(1989).
RN [19]
RP SYNTHESIS (URODILATIN), FUNCTION (URODILATIN), AND PHOSPHORYLATION AT
RP SER-129 (URODILATIN).
RX PubMed=2528951; DOI=10.1016/0006-291x(89)92297-3;
RA Doerner T., Gagelmann M., Feller S., Herbst F., Forssmann W.G.;
RT "Phosphorylation and dephosphorylation of the natriuretic peptide
RT urodilatin (CDD-/ANP-95-126) and the effect on biological activity.";
RL Biochem. Biophys. Res. Commun. 163:830-835(1989).
RN [20]
RP FUNCTION (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL DILATOR AND ATRIAL
RP NATRIURETIC PEPTIDE).
RX PubMed=2162527; DOI=10.1016/0196-9781(90)90070-l;
RA Vesely D.L., Cornett L.E., MacLeod S.L., Nash A.A., Norris J.S.;
RT "Specific binding sites for prohormone atrial natriuretic peptides 1-30,
RT 31-67 and 99-126.";
RL Peptides 11:193-197(1990).
RN [21]
RP RECEPTOR-BINDING (ATRIAL NATRIURETIC PEPTIDE).
RX PubMed=1660465; DOI=10.1016/s0021-9258(18)54463-x;
RA Bennett B.D., Bennett G.L., Vitangcol R.V., Jewett J.R., Burnier J.,
RA Henzel W., Lowe D.G.;
RT "Extracellular domain-IgG fusion proteins for three human natriuretic
RT peptide receptors. Hormone pharmacology and application to solid phase
RT screening of synthetic peptide antisera.";
RL J. Biol. Chem. 266:23060-23067(1991).
RN [22]
RP FUNCTION (ATRIAL NATRIURETIC PEPTIDE).
RX PubMed=1672777; DOI=10.1126/science.1672777;
RA Koller K.J., Lowe D.G., Bennett G.L., Minamino N., Kangawa K., Matsuo H.,
RA Goeddel D.V.;
RT "Selective activation of the B natriuretic peptide receptor by C-type
RT natriuretic peptide (CNP).";
RL Science 252:120-123(1991).
RN [23]
RP FUNCTION (ATRIAL NATRIURETIC PEPTIDE AND URODILATIN), AND TISSUE
RP SPECIFICITY (ATRIAL NATRIURETIC PEPTIDE AND URODILATIN).
RX PubMed=8384600; DOI=10.1161/01.hyp.21.4.432;
RA Valentin J.P., Sechi L.A., Qui C., Schambelan M., Humphreys M.H.;
RT "Urodilatin binds to and activates renal receptors for atrial natriuretic
RT peptide.";
RL Hypertension 21:432-438(1993).
RN [24]
RP SYNTHESIS (URODILATIN), FUNCTION (URODILATIN), SUBCELLULAR LOCATION (ATRIAL
RP NATRIURETIC PEPTIDE AND URODILATIN), TISSUE SPECIFICITY (ATRIAL NATRIURETIC
RP PEPTIDE AND URODILATIN), AND PROTEOLYTIC PROCESSING (URODILATIN).
RX PubMed=8351194; DOI=10.1007/bf00374930;
RA Drummer C., Fiedler F., Bub A., Kleefeld D., Dimitriades E., Gerzer R.,
RA Forssmann W.G.;
RT "Development and application of a urodilatin (CDD/ANP-95-126)-specific
RT radioimmunoassay.";
RL Pflugers Arch. 423:372-377(1993).
RN [25]
RP SYNTHESIS (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL DILATOR; KALIURETIC
RP PEPTIDE AND ATRIAL NATRIURETIC PEPTIDE), AND FUNCTION (LONG-ACTING
RP NATRIURETIC PEPTIDE; VESSEL DILATOR; KALIURETIC PEPTIDE AND ATRIAL
RP NATRIURETIC PEPTIDE).
RX PubMed=8087923; DOI=10.1161/01.cir.90.3.1129;
RA Vesely D.L., Douglass M.A., Dietz J.R., Gower W.R. Jr., McCormick M.T.,
RA Rodriguez-Paz G., Schocken D.D.;
RT "Three peptides from the atrial natriuretic factor prohormone amino
RT terminus lower blood pressure and produce diuresis, natriuresis, and/or
RT kaliuresis in humans.";
RL Circulation 90:1129-1140(1994).
RN [26]
RP SYNTHESIS (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL DILATOR AND ATRIAL
RP NATRIURETIC PEPTIDE), FUNCTION (LONG-ACTING NATRIURETIC PEPTIDE AND VESSEL
RP DILATOR), SUBCELLULAR LOCATION (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL
RP DILATOR AND ATRIAL NATRIURETIC PEPTIDE), AND PROTEOLYTIC PROCESSING.
RX PubMed=7955907; DOI=10.1042/cs0870311;
RA Buckley M.G., Markandu N.D., Sagnella G.A., MacGregor G.A.;
RT "N-terminal atrial natriuretic peptide and atrial natriuretic peptide in
RT human plasma: investigation of plasma levels and molecular circulating
RT form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67),
RT pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-
RT 126).";
RL Clin. Sci. 87:311-317(1994).
RN [27]
RP SYNTHESIS (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL DILATOR; KALIURETIC
RP PEPTIDE AND ATRIAL NATRIURETIC PEPTIDE), SUBCELLULAR LOCATION (LONG-ACTING
RP NATRIURETIC PEPTIDE; VESSEL DILATOR; KALIURETIC PEPTIDE AND ATRIAL
RP NATRIURETIC PEPTIDE), TISSUE SPECIFICITY (ATRIAL NATRIURETIC PEPTIDE), AND
RP PROTEOLYTIC PROCESSING.
RX PubMed=7984506; DOI=10.1016/0196-9781(94)90043-4;
RA Gower W.R. Jr., Chiou S., Skolnick K.A., Vesely D.L.;
RT "Molecular forms of circulating atrial natriuretic peptides in human plasma
RT and their metabolites.";
RL Peptides 15:861-867(1994).
RN [28]
RP FUNCTION (VESSEL DILATOR).
RX PubMed=7831500; DOI=10.1016/0167-0115(94)90612-2;
RA Weir M.L., Honrath U., Flynn T.G., Sonnenberg H.;
RT "Lack of biologic activity or specific binding of amino-terminal pro-ANP
RT segments in the rat.";
RL Regul. Pept. 53:111-122(1994).
RN [29]
RP FUNCTION (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL DILATOR AND ATRIAL
RP NATRIURETIC PEPTIDE), AND SUBCELLULAR LOCATION (LONG-ACTING NATRIURETIC
RP PEPTIDE; VESSEL DILATOR AND ATRIAL NATRIURETIC PEPTIDE).
RX PubMed=8653797; DOI=10.3109/07420529509064506;
RA Sothern R.B., Vesely D.L., Kanabrocki E.L., Hermida R.C., Bremner F.W.,
RA Third J.L., Boles M.A., Nemchausky B.M., Olwin J.H., Scheving L.E.;
RT "Temporal (circadian) and functional relationship between atrial
RT natriuretic peptides and blood pressure.";
RL Chronobiol. Int. 12:106-120(1995).
RN [30]
RP SYNTHESIS (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL DILATOR; KALIURETIC
RP PEPTIDE AND ATRIAL NATRIURETIC PEPTIDE), AND FUNCTION (LONG-ACTING
RP NATRIURETIC PEPTIDE; VESSEL DILATOR; KALIURETIC PEPTIDE AND ATRIAL
RP NATRIURETIC PEPTIDE).
RX PubMed=7720651; DOI=10.1210/endo.136.5.7720651;
RA Chiou S., Vesely D.L.;
RT "Kaliuretic peptide: the most potent inhibitor of Na(+)-K+ ATPase of the
RT atrial natriuretic peptides.";
RL Endocrinology 136:2033-2039(1995).
RN [31]
RP SYNTHESIS (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL DILATOR; KALIURETIC
RP PEPTIDE AND ATRIAL NATRIURETIC PEPTIDE), AND FUNCTION (LONG-ACTING
RP NATRIURETIC PEPTIDE; VESSEL DILATOR; KALIURETIC PEPTIDE AND ATRIAL
RP NATRIURETIC PEPTIDE).
RX PubMed=7595132; DOI=10.1677/joe.0.1460373;
RA Vesely D.L., Chiou S., Douglass M.A., McCormick M.T., Rodriguez-Paz G.,
RA Schocken D.D.;
RT "Kaliuretic peptide and long acting natriuretic peptide as well as atrial
RT natriuretic factor inhibit aldosterone secretion.";
RL J. Endocrinol. 146:373-380(1995).
RN [32]
RP FUNCTION (URODILATIN), SUBCELLULAR LOCATION (ATRIAL NATRIURETIC PEPTIDE AND
RP URODILATIN), AND TISSUE SPECIFICITY (URODILATIN).
RX PubMed=8779891; DOI=10.1152/ajprenal.1996.270.2.f301;
RA Drummer C., Franck W., Heer M., Forssmann W.G., Gerzer R., Goetz K.;
RT "Postprandial natriuresis in humans: further evidence that urodilatin, not
RT ANP, modulates sodium excretion.";
RL Am. J. Physiol. 270:F301-F310(1996).
RN [33]
RP FUNCTION (URODILATIN), AND SUBCELLULAR LOCATION (URODILATIN).
RX PubMed=8853410; DOI=10.1152/ajprenal.1996.271.3.f489;
RA Meyer M., Richter R., Brunkhorst R., Wrenger E., Schulz-Knappe P., Kist A.,
RA Mentz P., Brabant E.G., Koch K.M., Rechkemmer G., Forssmann W.G.;
RT "Urodilatin is involved in sodium homeostasis and exerts sodium-state-
RT dependent natriuretic and diuretic effects.";
RL Am. J. Physiol. 271:F489-F497(1996).
RN [34]
RP SUBCELLULAR LOCATION (URODILATIN), TISSUE SPECIFICITY (ATRIAL NATRIURETIC
RP PEPTIDE AND URODILATIN), AND PROTEOLYTIC PROCESSING (URODILATIN).
RX PubMed=9794555; DOI=10.1093/ndt/13.10.2529;
RA Herten M., Lenz W., Gerzer R., Drummer C.;
RT "The renal natriuretic peptide urodilatin is present in human kidney.";
RL Nephrol. Dial. Transplant. 13:2529-2535(1998).
RN [35]
RP FUNCTION (URODILATIN AND ATRIAL NATRIURETIC PEPTIDE), AND SUBCELLULAR
RP LOCATION (URODILATIN AND ATRIAL NATRIURETIC PEPTIDE).
RX PubMed=9893117; DOI=10.1046/j.1523-1755.1999.00242.x;
RA Lenz W., Herten M., Gerzer R., Drummer C.;
RT "Regulation of natriuretic peptide (urodilatin) release in a human kidney
RT cell line.";
RL Kidney Int. 55:91-99(1999).
RN [36]
RP FUNCTION (LONG-ACTING NATRIURETIC PEPTIDE; VESSEL DILATOR AND KALIURETIC
RP PEPTIDE).
RX PubMed=11145122; DOI=10.1053/meta.2000.18557;
RA Vesely D.L., Perez-Lamboy G.I., Schocken D.D.;
RT "Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide
RT enhance the urinary excretion rate of beta2-microglobulin.";
RL Metabolism 49:1592-1597(2000).
RN [37]
RP PROTEOLYTIC PROCESSING, CLEAVAGE SITE, AND MUTAGENESIS OF ARG-123.
RX PubMed=10880574; DOI=10.1073/pnas.150149097;
RA Yan W., Wu F., Morser J., Wu Q.;
RT "Corin, a transmembrane cardiac serine protease, acts as a pro-atrial
RT natriuretic peptide-converting enzyme.";
RL Proc. Natl. Acad. Sci. U.S.A. 97:8525-8529(2000).
RN [38]
RP PROTEOLYTIC PROCESSING.
RX PubMed=14559895; DOI=10.1074/jbc.m309991200;
RA Knappe S., Wu F., Masikat M.R., Morser J., Wu Q.;
RT "Functional analysis of the transmembrane domain and activation cleavage of
RT human corin: design and characterization of a soluble corin.";
RL J. Biol. Chem. 278:52363-52370(2003).
RN [39]
RP FUNCTION (ATRIAL NATRIURETIC PEPTIDE), AND SUBCELLULAR LOCATION (ATRIAL
RP NATRIURETIC PEPTIDE).
RX PubMed=15741263; DOI=10.1210/jc.2004-1953;
RA Birkenfeld A.L., Boschmann M., Moro C., Adams F., Heusser K., Franke G.,
RA Berlan M., Luft F.C., Lafontan M., Jordan J.;
RT "Lipid mobilization with physiological atrial natriuretic peptide
RT concentrations in humans.";
RL J. Clin. Endocrinol. Metab. 90:3622-3628(2005).
RN [40]
RP PROTEOLYTIC PROCESSING BY MME (ATRIAL NATRIURETIC PEPTIDE).
RX PubMed=16254193; DOI=10.1373/clinchem.2005.057638;
RA Brandt I., Lambeir A.M., Ketelslegers J.M., Vanderheyden M., Scharpe S.,
RA De Meester I.;
RT "Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into
RT its des-SerPro form.";
RL Clin. Chem. 52:82-87(2006).
RN [41]
RP FUNCTION (ATRIAL NATRIURETIC PEPTIDE), AND VARIANT ARG-ARG-151 EXT.
RX PubMed=16875975; DOI=10.1016/j.jacc.2005.12.081;
RA Rubattu S., Bigatti G., Evangelista A., Lanzani C., Stanzione R.,
RA Zagato L., Manunta P., Marchitti S., Venturelli V., Bianchi G., Volpe M.,
RA Stella P.;
RT "Association of atrial natriuretic peptide and type a natriuretic peptide
RT receptor gene polymorphisms with left ventricular mass in human essential
RT hypertension.";
RL J. Am. Coll. Cardiol. 48:499-505(2006).
RN [42]
RP FUNCTION (ATRIAL NATRIURETIC PEPTIDE), AND SUBCELLULAR LOCATION (ATRIAL
RP NATRIURETIC PEPTIDE).
RX PubMed=18835931; DOI=10.2337/db08-0649;
RA Birkenfeld A.L., Budziarek P., Boschmann M., Moro C., Adams F., Franke G.,
RA Berlan M., Marques M.A., Sweep F.C., Luft F.C., Lafontan M., Jordan J.;
RT "Atrial natriuretic peptide induces postprandial lipid oxidation in
RT humans.";
RL Diabetes 57:3199-3204(2008).
RN [43]
RP FUNCTION (ATRIAL NATRIURETIC PEPTIDE), AND TISSUE SPECIFICITY (ATRIAL
RP NATRIURETIC PEPTIDE).
RX PubMed=21672517; DOI=10.1016/j.bbrc.2011.05.143;
RA Souza S.C., Chau M.D., Yang Q., Gauthier M.S., Clairmont K.B., Wu Z.,
RA Gromada J., Dole W.P.;
RT "Atrial natriuretic peptide regulates lipid mobilization and oxygen
RT consumption in human adipocytes by activating AMPK.";
RL Biochem. Biophys. Res. Commun. 410:398-403(2011).
RN [44]
RP TISSUE SPECIFICITY (ATRIAL NATRIURETIC PEPTIDE).
RX PubMed=22291141; DOI=10.1373/clinchem.2011.176990;
RA Pemberton C.J., Siriwardena M., Kleffmann T., Ruygrok P., Palmer S.C.,
RA Yandle T.G., Richards A.M.;
RT "First identification of circulating prepro-A-type natriuretic peptide
RT (preproANP) signal peptide fragments in humans: initial assessment as
RT cardiovascular biomarkers.";
RL Clin. Chem. 58:757-767(2012).
RN [45]
RP FUNCTION (ATRIAL NATRIURETIC PEPTIDE).
RX PubMed=22307324; DOI=10.1172/jci59701;
RA Bordicchia M., Liu D., Amri E.Z., Ailhaud G., Dessi-Fulgheri P., Zhang C.,
RA Takahashi N., Sarzani R., Collins S.;
RT "Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat
RT thermogenic program in mouse and human adipocytes.";
RL J. Clin. Invest. 122:1022-1036(2012).
RN [46]
RP FUNCTION (ATRIAL NATRIURETIC PEPTIDE).
RX PubMed=25401746; DOI=10.1371/journal.pone.0113108;
RA Rubattu S., Marchitti S., Bianchi F., Di Castro S., Stanzione R.,
RA Cotugno M., Bozzao C., Sciarretta S., Volpe M.;
RT "The C2238/alphaANP variant is a negative modulator of both viability and
RT function of coronary artery smooth muscle cells.";
RL PLoS ONE 9:E113108-E113108(2014).
RN [47]
RP SUBCELLULAR LOCATION (ATRIAL NATRIURETIC PEPTIDE), AND TISSUE SPECIFICITY
RP (ATRIAL NATRIURETIC PEPTIDE).
RX PubMed=30534047; DOI=10.3389/fnins.2018.00864;
RA Mahinrad S., Bulk M., van der Velpen I., Mahfouz A., van Roon-Mom W.,
RA Fedarko N., Yasar S., Sabayan B., van Heemst D., van der Weerd L.;
RT "Natriuretic Peptides in Post-mortem Brain Tissue and Cerebrospinal Fluid
RT of Non-demented Humans and Alzheimer's Disease Patients.";
RL Front. Neurosci. 12:864-864(2018).
RN [48]
RP STRUCTURE BY NMR OF 124-151 MUTANT SELECTIVE FOR NPR-C RECEPTOR.
RX PubMed=8043577; DOI=10.1021/bi00196a006;
RA Fairbrother W.J., McDowell R.S., Cunningham B.C.;
RT "Solution conformation of an atrial natriuretic peptide variant selective
RT for the type A receptor.";
RL Biochemistry 33:8897-8904(1994).
RN [49]
RP X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 129-149 IN COMPLEX WITH NPR3, AND
RP DISULFIDE BOND.
RX PubMed=16870210; DOI=10.1016/j.jmb.2006.06.060;
RA He X.-L., Dukkipati A., Garcia K.C.;
RT "Structural determinants of natriuretic peptide receptor specificity and
RT degeneracy.";
RL J. Mol. Biol. 361:698-714(2006).
RN [50] {ECO:0007744|PDB:3N57}
RP X-RAY CRYSTALLOGRAPHY (3.03 ANGSTROMS) OF 124-151, FUNCTION (ATRIAL
RP NATRIURETIC PEPTIDE), PROTEOLYTIC DEGRADATION BY IDE (ATRIAL NATRIURETIC
RP PEPTIDE AND URODILATIN), REGION, AND MUTAGENESIS OF 124-SER--ARG-126;
RP 124-SER--SER-129 AND 147-ASN--TYR-151.
RX PubMed=21098034; DOI=10.1074/jbc.m110.173252;
RA Ralat L.A., Guo Q., Ren M., Funke T., Dickey D.M., Potter L.R., Tang W.J.;
RT "Insulin-degrading enzyme modulates the natriuretic peptide-mediated
RT signaling response.";
RL J. Biol. Chem. 286:4670-4679(2011).
RN [51]
RP INVOLVEMENT IN ATFB6.
RX PubMed=18614783; DOI=10.1056/nejmoa0706300;
RA Hodgson-Zingman D.M., Karst M.L., Zingman L.V., Heublein D.M., Darbar D.,
RA Herron K.J., Ballew J.D., de Andrade M., Burnett J.C. Jr., Olson T.M.;
RT "Atrial natriuretic peptide frameshift mutation in familial atrial
RT fibrillation.";
RL N. Engl. J. Med. 359:158-165(2008).
RN [52]
RP INVOLVEMENT IN ATRST2, AND VARIANT ATRST2 GLN-150.
RX PubMed=23275345; DOI=10.1161/circgenetics.112.963520;
RA Disertori M., Quintarelli S., Grasso M., Pilotto A., Narula N., Favalli V.,
RA Canclini C., Diegoli M., Mazzola S., Marini M., Del Greco M.,
RA Bonmassari R., Mase M., Ravelli F., Specchia C., Arbustini E.;
RT "Autosomal recessive atrial dilated cardiomyopathy with standstill
RT evolution associated with mutation of natriuretic peptide precursor A.";
RL Circ. Cardiovasc. Genet. 6:27-36(2013).
CC -!- FUNCTION: [Atrial natriuretic peptide]: Hormone that plays a key role
CC in mediating cardio-renal homeostasis, and is involved in vascular
CC remodeling and regulating energy metabolism (PubMed:8653797,
CC PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:8087923,
CC PubMed:2532366, PubMed:22307324, PubMed:18835931, PubMed:21672517,
CC PubMed:15741263, PubMed:16875975). Acts by specifically binding and
CC stimulating NPR1 to produce cGMP, which in turn activates effector
CC proteins, such as PRKG1, that drive various biological responses
CC (PubMed:25401746, PubMed:9893117, PubMed:1672777, PubMed:1660465,
CC PubMed:2162527, PubMed:2825692, PubMed:7720651, PubMed:22307324,
CC PubMed:8384600, PubMed:21098034). Regulates vasodilation, natriuresis,
CC diuresis and aldosterone synthesis and is therefore essential for
CC regulating blood pressure, controlling the extracellular fluid volume
CC and maintaining the fluid-electrolyte balance (PubMed:8653797,
CC PubMed:7595132, PubMed:2825692, PubMed:7720651, PubMed:2532366,
CC PubMed:8087923). Also involved in inhibiting cardiac remodeling and
CC cardiac hypertrophy by inducing cardiomyocyte apoptosis and attenuating
CC the growth of cardiomyocytes and fibroblasts (PubMed:16875975). Plays a
CC role in female pregnancy by promoting trophoblast invasion and spiral
CC artery remodeling in uterus, and thus prevents pregnancy-induced
CC hypertension (By similarity). In adipose tissue, acts in various
CC cGMP- and PKG-dependent pathways to regulate lipid metabolism and
CC energy homeostasis (PubMed:22307324, PubMed:18835931, PubMed:21672517,
CC PubMed:15741263). This includes up-regulating lipid metabolism and
CC mitochondrial oxygen utilization by activating the AMP-activated
CC protein kinase (AMPK), and increasing energy expenditure by acting via
CC MAPK11 to promote the UCP1-dependent thermogenesis of brown adipose
CC tissue (PubMed:22307324, PubMed:18835931, PubMed:21672517,
CC PubMed:15741263). Binds the clearance receptor NPR3 which removes the
CC hormone from circulation (PubMed:1672777).
CC {ECO:0000250|UniProtKB:P05125, ECO:0000269|PubMed:15741263,
CC ECO:0000269|PubMed:1660465, ECO:0000269|PubMed:1672777,
CC ECO:0000269|PubMed:16875975, ECO:0000269|PubMed:18835931,
CC ECO:0000269|PubMed:21098034, ECO:0000269|PubMed:2162527,
CC ECO:0000269|PubMed:21672517, ECO:0000269|PubMed:22307324,
CC ECO:0000269|PubMed:2532366, ECO:0000269|PubMed:25401746,
CC ECO:0000269|PubMed:2825692, ECO:0000269|PubMed:7595132,
CC ECO:0000269|PubMed:7720651, ECO:0000269|PubMed:8087923,
CC ECO:0000269|PubMed:8384600, ECO:0000269|PubMed:8653797,
CC ECO:0000269|PubMed:9893117}.
CC -!- FUNCTION: [Long-acting natriuretic peptide]: May have a role in cardio-
CC renal homeostasis through regulation of natriuresis, diuresis,
CC vasodilation, and inhibiting aldosterone synthesis (PubMed:8653797,
CC PubMed:7955907, PubMed:8087923, PubMed:2825692, PubMed:7595132,
CC PubMed:2532366). In vitro, promotes the production of cGMP and induces
CC vasodilation (PubMed:2825692). May promote natriuresis, at least in
CC part, by enhancing prostaglandin E2 synthesis resulting in the
CC inhibition of renal Na+-K+-ATPase (PubMed:7720651). However reports on
CC the involvement of this peptide in mammal blood volume and blood
CC pressure homeostasis are conflicting; according to a report, in vivo it
CC is not sufficient to activate cGMP and does not inhibit collecting duct
CC transport nor effect diuresis and natriuresis (By similarity). Appears
CC to bind to specific receptors that are distinct from the receptors
CC bound by atrial natriuretic peptide and vessel dilator (PubMed:2162527,
CC PubMed:2825692). Possibly enhances protein excretion in urine by
CC decreasing proximal tubular protein reabsorption (PubMed:11145122).
CC {ECO:0000250|UniProtKB:P01161, ECO:0000269|PubMed:11145122,
CC ECO:0000269|PubMed:2162527, ECO:0000269|PubMed:2532366,
CC ECO:0000269|PubMed:2825692, ECO:0000269|PubMed:7595132,
CC ECO:0000269|PubMed:7720651, ECO:0000269|PubMed:7955907,
CC ECO:0000269|PubMed:8087923, ECO:0000269|PubMed:8653797}.
CC -!- FUNCTION: [Vessel dilator]: May have a role in cardio-renal homeostasis
CC through regulation of natriuresis, diuresis, and vasodilation
CC (PubMed:8653797, PubMed:7955907, PubMed:8087923, PubMed:2532366,
CC PubMed:7595132). In vitro, promotes the production of cGMP and induces
CC vasodilation (PubMed:2825692). May promote natriuresis, at least in
CC part, by enhancing prostaglandin E2 synthesis resulting in the
CC inhibition of renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132).
CC However reports on the involvement of this peptide in mammal blood
CC volume and blood pressure homeostasis are conflicting; according to a
CC report it is not sufficient to activate cGMP and does not inhibit
CC collecting duct transport nor effect diuresis and natriuresis
CC (PubMed:7831500). Appears to bind to specific receptors that are
CC distinct from the receptors bound by the atrial natriuretic and long-
CC acting natriuretic peptides (PubMed:2162527, PubMed:2825692). Possibly
CC functions in protein excretion in urine by maintaining the integrity of
CC the proximal tubules and enhancing protein excretion by decreasing
CC proximal tubular protein reabsorption (PubMed:11145122).
CC {ECO:0000269|PubMed:11145122, ECO:0000269|PubMed:2162527,
CC ECO:0000269|PubMed:2532366, ECO:0000269|PubMed:2825692,
CC ECO:0000269|PubMed:7595132, ECO:0000269|PubMed:7720651,
CC ECO:0000269|PubMed:7831500, ECO:0000269|PubMed:7955907,
CC ECO:0000269|PubMed:8087923, ECO:0000269|PubMed:8653797}.
CC -!- FUNCTION: [Kaliuretic peptide]: May have a role in cardio-renal
CC homeostasis through regulation of diuresis and inhibiting aldosterone
CC synthesis (PubMed:8087923, PubMed:2825692, PubMed:7595132). In vitro,
CC promotes the production of cGMP and induces vasodilation
CC (PubMed:2825692). May promote natriuresis, at least in part, by
CC enhancing prostaglandin E2 synthesis resulting in the inhibition of
CC renal Na+-K+-ATPase (PubMed:7720651, PubMed:7595132). May have a role
CC in potassium excretion but not sodium excretion (natriuresis)
CC (PubMed:8087923). Possibly enhances protein excretion in urine by
CC decreasing proximal tubular protein reabsorption (PubMed:11145122).
CC {ECO:0000269|PubMed:11145122, ECO:0000269|PubMed:2825692,
CC ECO:0000269|PubMed:7595132, ECO:0000269|PubMed:7720651,
CC ECO:0000269|PubMed:8087923}.
CC -!- FUNCTION: [Urodilatin]: Hormone produced in the kidneys that appears to
CC be important for maintaining cardio-renal homeostasis (PubMed:8351194,
CC PubMed:8853410, PubMed:8779891). Mediates vasodilation, natriuresis and
CC diuresis primarily in the renal system, in order to maintain the
CC extracellular fluid volume and control the fluid-electrolyte balance
CC (PubMed:2528951, PubMed:8351194, PubMed:8853410, PubMed:8779891).
CC Specifically binds and stimulates cGMP production by renal
CC transmembrane receptors, likely NPR1 (PubMed:8384600, PubMed:9893117).
CC Urodilatin not ANP, may be the natriuretic peptide responsible for the
CC regulation of sodium and water homeostasis in the kidney
CC (PubMed:8779891, PubMed:8384600). {ECO:0000269|PubMed:2528951,
CC ECO:0000269|PubMed:8351194, ECO:0000269|PubMed:8384600,
CC ECO:0000269|PubMed:8779891, ECO:0000269|PubMed:8853410,
CC ECO:0000269|PubMed:9893117}.
CC -!- FUNCTION: [Auriculin-D]: May have a role in cardio-renal homeostasis
CC through regulation of natriuresis and vasodilation. In vivo promotes
CC natriuresis and in vitro, vasodilates renal artery strips.
CC {ECO:0000250|UniProtKB:P01161}.
CC -!- FUNCTION: [Auriculin-B]: May have a role in cardio-renal homeostasis
CC through regulation of natriuresis and vasodilation. In vivo promotes
CC natriuresis and in vitro, vasodilates renal artery strips.
CC {ECO:0000250|UniProtKB:P01161}.
CC -!- FUNCTION: [Auriculin-A]: May have a role in cardio-renal homeostasis
CC through regulation of regulation of natriuresis and vasodilation. In
CC vivo promotes natriuresis. In vitro, vasodilates intestinal smooth
CC muscle but not smooth muscle strips. {ECO:0000250|UniProtKB:P01161}.
CC -!- FUNCTION: [Atriopeptin-2]: May have a role in cardio-renal homeostasis
CC through regulation of natriuresis and vasodilation. In vivo promotes
CC natriuresis. In vitro, selectively vasodilates intestinal and vascular
CC smooth muscle strips. {ECO:0000250|UniProtKB:P01161}.
CC -!- FUNCTION: [Atriopeptin-1]: May have a role in cardio-renal homeostasis
CC through regulation of natriuresis and vasodilation. In vivo promotes
CC natriuresis. In vitro, selectively vasodilates intestinal smooth muscle
CC but not vascular smooth muscle strips. {ECO:0000250|UniProtKB:P01161}.
CC -!- SUBUNIT: [Atrial natriuretic peptide]: Homodimer; disulfide-linked
CC antiparallel dimer. {ECO:0000269|PubMed:3838202}.
CC -!- INTERACTION:
CC P01160; O75031: HSF2BP; NbExp=3; IntAct=EBI-953859, EBI-7116203;
CC P01160; P43365: MAGEA12; NbExp=6; IntAct=EBI-953859, EBI-749530;
CC P01160; Q9UMX0: UBQLN1; NbExp=3; IntAct=EBI-953859, EBI-741480;
CC P01160; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-953859, EBI-947187;
CC -!- SUBCELLULAR LOCATION: [Long-acting natriuretic peptide]: Secreted
CC {ECO:0000269|PubMed:2532366, ECO:0000269|PubMed:7955907,
CC ECO:0000269|PubMed:7984506, ECO:0000269|PubMed:8653797}. Note=Detected
CC in blood. {ECO:0000269|PubMed:2532366, ECO:0000269|PubMed:7955907,
CC ECO:0000269|PubMed:7984506, ECO:0000269|PubMed:8653797}.
CC -!- SUBCELLULAR LOCATION: [Vessel dilator]: Secreted
CC {ECO:0000269|PubMed:2532366, ECO:0000269|PubMed:7955907,
CC ECO:0000269|PubMed:7984506, ECO:0000269|PubMed:8653797}. Note=Detected
CC in blood. {ECO:0000269|PubMed:2532366, ECO:0000269|PubMed:7955907,
CC ECO:0000269|PubMed:7984506, ECO:0000269|PubMed:8653797}.
CC -!- SUBCELLULAR LOCATION: [Kaliuretic peptide]: Secreted
CC {ECO:0000269|PubMed:7984506}. Note=Detected in blood.
CC {ECO:0000269|PubMed:7984506}.
CC -!- SUBCELLULAR LOCATION: [Urodilatin]: Secreted
CC {ECO:0000269|PubMed:2972874, ECO:0000269|PubMed:8351194,
CC ECO:0000269|PubMed:8779891, ECO:0000269|PubMed:8853410,
CC ECO:0000269|PubMed:9794555, ECO:0000269|PubMed:9893117}. Note=Detected
CC in urine (PubMed:2972874, PubMed:9794555, PubMed:8351194,
CC PubMed:8779891). Not detected in blood (PubMed:8351194). Increased
CC electrolytes, osmolality and intracellular cAMP levels increase peptide
CC secretion/excretion (PubMed:9893117, PubMed:8853410, PubMed:8351194,
CC PubMed:8779891). {ECO:0000269|PubMed:2972874,
CC ECO:0000269|PubMed:8351194, ECO:0000269|PubMed:8779891,
CC ECO:0000269|PubMed:8853410, ECO:0000269|PubMed:9794555,
CC ECO:0000269|PubMed:9893117}.
CC -!- SUBCELLULAR LOCATION: [Atrial natriuretic peptide]: Secreted
CC {ECO:0000269|PubMed:15741263, ECO:0000269|PubMed:18835931,
CC ECO:0000269|PubMed:2532366, ECO:0000269|PubMed:2972874,
CC ECO:0000269|PubMed:7955907, ECO:0000269|PubMed:7984506,
CC ECO:0000269|PubMed:8351194, ECO:0000269|PubMed:8653797,
CC ECO:0000269|PubMed:8779891, ECO:0000269|PubMed:9893117}. Perikaryon
CC {ECO:0000269|PubMed:30534047}. Cell projection
CC {ECO:0000269|PubMed:30534047}. Note=Detected in blood (PubMed:8351194,
CC PubMed:8779891, PubMed:7955907, PubMed:8653797, PubMed:15741263,
CC PubMed:18835931, PubMed:2532366, PubMed:7984506). Detected in urine in
CC one study (PubMed:8351194). However, in another study, was not detected
CC in urine (PubMed:7984506). Detected in cytoplasmic bodies and neuronal
CC processes of pyramidal neurons (layers II-VI) (PubMed:30534047).
CC Increased secretion in response to the vasopressin AVP (By similarity).
CC Likely to be secreted in response to an increase in atrial pressure or
CC atrial stretch (PubMed:2532366). In kidney cells, secretion increases
CC in response to activated guanylyl cyclases and increased intracellular
CC cAMP levels (PubMed:9893117). Plasma levels increase 15 minutes after a
CC high-salt meal, and decrease back to normal plasma levels 1 hr later
CC (PubMed:8779891). {ECO:0000250|UniProtKB:P01161,
CC ECO:0000269|PubMed:15741263, ECO:0000269|PubMed:18835931,
CC ECO:0000269|PubMed:2532366, ECO:0000269|PubMed:30534047,
CC ECO:0000269|PubMed:7955907, ECO:0000269|PubMed:7984506,
CC ECO:0000269|PubMed:8351194, ECO:0000269|PubMed:8653797,
CC ECO:0000269|PubMed:8779891, ECO:0000269|PubMed:9893117}.
CC -!- SUBCELLULAR LOCATION: [Atriopeptin-3]: Secreted
CC {ECO:0000250|UniProtKB:P01161}. Note=Detected in blood. Slight increase
CC in secretion in response to the vasopressin AVP.
CC {ECO:0000250|UniProtKB:P01161}.
CC -!- TISSUE SPECIFICITY: [Urodilatin]: Detected in the kidney distal tubular
CC cells (at protein level) (PubMed:9794555, PubMed:8384600). Present in
CC urine (at protein level) (PubMed:2972874, PubMed:9794555,
CC PubMed:8351194, PubMed:8779891). {ECO:0000269|PubMed:2972874,
CC ECO:0000269|PubMed:8351194, ECO:0000269|PubMed:8384600,
CC ECO:0000269|PubMed:8779891, ECO:0000269|PubMed:9794555}.
CC -!- TISSUE SPECIFICITY: [Atrial natriuretic peptide]: Detected in atrial
CC and ventricular plasma samples, and in adipocytes (at protein level)
CC (PubMed:22291141, PubMed:21672517). Detected in urine in one study
CC (PubMed:8351194). However, was not detected in urine in another study
CC (PubMed:7984506). In the brain, predominantly expressed in the gray
CC matter with very weak expression in the white matter (at protein level)
CC (PubMed:30534047). Localizes to astrocyte-like structures throughout
CC the white matter, and in the cerebral vessels detected in the
CC leptomeningeal and parenchymal vessels, and endothelium and smooth
CC muscle layers (at protein level) (PubMed:30534047). Relatively low
CC levels of expression in the kidneys compared to urodilatin (at protein
CC level) (PubMed:9794555, PubMed:8384600). {ECO:0000269|PubMed:21672517,
CC ECO:0000269|PubMed:22291141, ECO:0000269|PubMed:30534047,
CC ECO:0000269|PubMed:7984506, ECO:0000269|PubMed:8351194,
CC ECO:0000269|PubMed:8384600, ECO:0000269|PubMed:9794555}.
CC -!- PTM: The precursor molecule is proteolytically cleaved by CORIN at Arg-
CC 123 to produce atrial natriuretic peptide (PubMed:10880574,
CC PubMed:14559895, PubMed:7984506). Undergoes further proteolytic
CC cleavage by unknown proteases to give rise to long-acting natriuretic
CC peptide, vessel dilator and kaliuretic peptide (PubMed:2532366,
CC PubMed:7955907, PubMed:7984506). Additional processing gives rise to
CC the auriculin and atriopeptin peptides (By similarity). In the kidneys,
CC alternative processing by an unknown protease results in the peptide
CC urodilatin (PubMed:2972874, PubMed:8351194, PubMed:9794555).
CC {ECO:0000250|UniProtKB:P01161, ECO:0000269|PubMed:10880574,
CC ECO:0000269|PubMed:14559895, ECO:0000269|PubMed:2532366,
CC ECO:0000269|PubMed:2972874, ECO:0000269|PubMed:7955907,
CC ECO:0000269|PubMed:7984506, ECO:0000269|PubMed:8351194,
CC ECO:0000269|PubMed:9794555}.
CC -!- PTM: [Atrial natriuretic peptide]: Cleavage by MME initiates
CC degradation of the factor and thereby regulates its activity
CC (PubMed:2972276, PubMed:16254193). Degraded by IDE (in vitro)
CC (PubMed:21098034). During IDE degradation, the resulting products can
CC temporarily stimulate NPR2 to produce cGMP, before the fragments are
CC completely degraded and inactivated by IDE (in vitro)
CC (PubMed:21098034). {ECO:0000269|PubMed:16254193,
CC ECO:0000269|PubMed:21098034, ECO:0000269|PubMed:2972276}.
CC -!- PTM: [Urodilatin]: Degraded by IDE. {ECO:0000269|PubMed:21098034}.
CC -!- PTM: [Urodilatin]: Phosphorylation on Ser-129 decreases vasorelaxant
CC activity. {ECO:0000269|PubMed:2528951}.
CC -!- DISEASE: Atrial standstill 2 (ATRST2) [MIM:615745]: A rare arrhythmia
CC characterized by the absence of electrical and mechanical activity in
CC the atria. Electrocardiographically, it is characterized by
CC bradycardia, the absence of P waves, and a junctional narrow complex
CC escape rhythm. {ECO:0000269|PubMed:23275345}. Note=The disease is
CC caused by variants affecting the gene represented in this entry.
CC -!- DISEASE: Atrial fibrillation, familial, 6 (ATFB6) [MIM:612201]: A
CC familial form of atrial fibrillation, a common sustained cardiac rhythm
CC disturbance. Atrial fibrillation is characterized by disorganized
CC atrial electrical activity and ineffective atrial contraction promoting
CC blood stasis in the atria and reduces ventricular filling. It can
CC result in palpitations, syncope, thromboembolic stroke, and congestive
CC heart failure. {ECO:0000269|PubMed:18614783}. Note=The disease is
CC caused by variants affecting the gene represented in this entry.
CC -!- SIMILARITY: Belongs to the natriuretic peptide family. {ECO:0000305}.
CC -!- CAUTION: [Long-acting natriuretic peptide]: Results concerning the
CC involvement of this peptide in blood volume and blood pressure
CC homeostasis are conflicting. Several studies utilising in vitro and
CC heterologous expression systems show that it is able to activate cGMP
CC and promote vasodilation and natriuresis (PubMed:2825692,
CC PubMed:7720651). However, an in vivo study in rat found that it is not
CC sufficient to induce any diuretic, natriuretic, nor hypotensive
CC responses, and is unable to bind NPR1 nor increase guanylyl cyclase
CC activity (By similarity). {ECO:0000250|UniProtKB:P01161,
CC ECO:0000269|PubMed:2825692, ECO:0000269|PubMed:7720651}.
CC -!- CAUTION: [Vessel dilator]: Results concerning the involvement of this
CC peptide in blood volume and blood pressure homeostasis are conflicting.
CC Several studies utilising in vitro and heterologous expression systems
CC show that it is able to activate cGMP and promote vasodilation and
CC natriuresis (PubMed:2825692, PubMed:7720651, PubMed:7595132). However,
CC a heterologous expression study in rat found that it is not sufficient
CC to induce any diuretic, natriuretic, nor hypotensive responses, and is
CC unable to bind NPR1 nor increase guanylyl cyclase activity
CC (PubMed:7831500). {ECO:0000269|PubMed:2825692,
CC ECO:0000269|PubMed:7595132, ECO:0000269|PubMed:7720651,
CC ECO:0000269|PubMed:7831500}.
CC -!- WEB RESOURCE: Name=Wikipedia; Note=Atrial natriuretic peptide entry;
CC URL="https://en.wikipedia.org/wiki/Atrial_natriuretic_peptide";
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; K02043; AAB59379.1; -; Genomic_DNA.
DR EMBL; M30262; AAA35669.1; -; mRNA.
DR EMBL; X01470; CAA25699.1; -; Genomic_DNA.
DR EMBL; X02558; CAA25699.1; JOINED; Genomic_DNA.
DR EMBL; X01471; CAA25700.2; -; Genomic_DNA.
DR EMBL; M54951; AAA35529.1; -; Genomic_DNA.
DR EMBL; M54947; AAA35529.1; JOINED; Genomic_DNA.
DR EMBL; AL021155; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR EMBL; EU326308; ACA05916.1; -; Genomic_DNA.
DR EMBL; BC005893; AAH05893.1; -; mRNA.
DR EMBL; K02399; AAA35528.1; -; Genomic_DNA.
DR EMBL; K02044; AAA51730.1; -; mRNA.
DR CCDS; CCDS139.1; -.
DR PIR; A22693; AWHU.
DR RefSeq; NP_006163.1; NM_006172.3.
DR PDB; 1ANP; NMR; -; A=124-151.
DR PDB; 1YK0; X-ray; 2.40 A; E=129-149.
DR PDB; 3N57; X-ray; 3.03 A; C/D=124-151.
DR PDB; 7BRH; X-ray; 2.45 A; L=124-151.
DR PDB; 7BRJ; X-ray; 2.70 A; L=130-151.
DR PDB; 7BRK; X-ray; 2.85 A; L=128-150.
DR PDBsum; 1ANP; -.
DR PDBsum; 1YK0; -.
DR PDBsum; 3N57; -.
DR PDBsum; 7BRH; -.
DR PDBsum; 7BRJ; -.
DR PDBsum; 7BRK; -.
DR AlphaFoldDB; P01160; -.
DR SMR; P01160; -.
DR BioGRID; 110938; 57.
DR IntAct; P01160; 39.
DR STRING; 9606.ENSP00000365663; -.
DR ChEMBL; CHEMBL1293193; -.
DR CarbonylDB; P01160; -.
DR GlyGen; P01160; 1 site, 1 O-linked glycan (1 site).
DR iPTMnet; P01160; -.
DR PhosphoSitePlus; P01160; -.
DR BioMuta; NPPA; -.
DR DMDM; 113864; -.
DR MassIVE; P01160; -.
DR PaxDb; P01160; -.
DR PeptideAtlas; P01160; -.
DR PRIDE; P01160; -.
DR ProteomicsDB; 51340; -.
DR Antibodypedia; 13911; 763 antibodies from 40 providers.
DR DNASU; 4878; -.
DR Ensembl; ENST00000376480.7; ENSP00000365663.3; ENSG00000175206.11.
DR GeneID; 4878; -.
DR KEGG; hsa:4878; -.
DR MANE-Select; ENST00000376480.7; ENSP00000365663.3; NM_006172.4; NP_006163.1.
DR UCSC; uc001ati.4; human.
DR CTD; 4878; -.
DR DisGeNET; 4878; -.
DR GeneCards; NPPA; -.
DR HGNC; HGNC:7939; NPPA.
DR HPA; ENSG00000175206; Tissue enriched (heart).
DR MalaCards; NPPA; -.
DR MIM; 108780; gene.
DR MIM; 612201; phenotype.
DR MIM; 615745; phenotype.
DR neXtProt; NX_P01160; -.
DR OpenTargets; ENSG00000175206; -.
DR Orphanet; 1344; Atrial standstill.
DR Orphanet; 334; Familial atrial fibrillation.
DR PharmGKB; PA256; -.
DR VEuPathDB; HostDB:ENSG00000175206; -.
DR eggNOG; ENOG502S9RQ; Eukaryota.
DR GeneTree; ENSGT00940000154513; -.
DR InParanoid; P01160; -.
DR OMA; LSEVPPW; -.
DR OrthoDB; 1596502at2759; -.
DR PhylomeDB; P01160; -.
DR TreeFam; TF106304; -.
DR PathwayCommons; P01160; -.
DR Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR Reactome; R-HSA-5578768; Physiological factors.
DR Reactome; R-HSA-977225; Amyloid fiber formation.
DR SignaLink; P01160; -.
DR SIGNOR; P01160; -.
DR BioGRID-ORCS; 4878; 12 hits in 1062 CRISPR screens.
DR EvolutionaryTrace; P01160; -.
DR GeneWiki; Atrial_natriuretic_peptide; -.
DR GenomeRNAi; 4878; -.
DR Pharos; P01160; Tchem.
DR PRO; PR:P01160; -.
DR Proteomes; UP000005640; Chromosome 1.
DR RNAct; P01160; protein.
DR Bgee; ENSG00000175206; Expressed in cardiac muscle of right atrium and 148 other tissues.
DR ExpressionAtlas; P01160; baseline and differential.
DR Genevisible; P01160; HS.
DR GO; GO:0042995; C:cell projection; IEA:UniProtKB-SubCell.
DR GO; GO:0062023; C:collagen-containing extracellular matrix; HDA:BHF-UCL.
DR GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR GO; GO:0032991; C:protein-containing complex; IDA:CAFA.
DR GO; GO:0005179; F:hormone activity; IBA:GO_Central.
DR GO; GO:0051427; F:hormone receptor binding; IPI:UniProtKB.
DR GO; GO:0005184; F:neuropeptide hormone activity; IMP:BHF-UCL.
DR GO; GO:0071855; F:neuropeptide receptor binding; IMP:BHF-UCL.
DR GO; GO:0005102; F:signaling receptor binding; IDA:UniProtKB.
DR GO; GO:0003180; P:aortic valve morphogenesis; TAS:BHF-UCL.
DR GO; GO:0003161; P:cardiac conduction system development; NAS:BHF-UCL.
DR GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IEA:Ensembl.
DR GO; GO:0006182; P:cGMP biosynthetic process; IDA:GO_Central.
DR GO; GO:0019934; P:cGMP-mediated signaling; IBA:GO_Central.
DR GO; GO:0007565; P:female pregnancy; ISS:UniProtKB.
DR GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR GO; GO:0042059; P:negative regulation of epidermal growth factor receptor signaling pathway; IDA:UniProtKB.
DR GO; GO:0043508; P:negative regulation of JUN kinase activity; IDA:UniProtKB.
DR GO; GO:0003085; P:negative regulation of systemic arterial blood pressure; IBA:GO_Central.
DR GO; GO:0007218; P:neuropeptide signaling pathway; IDA:BHF-UCL.
DR GO; GO:0060452; P:positive regulation of cardiac muscle contraction; IMP:BHF-UCL.
DR GO; GO:1902261; P:positive regulation of delayed rectifier potassium channel activity; IDA:BHF-UCL.
DR GO; GO:0010460; P:positive regulation of heart rate; IMP:BHF-UCL.
DR GO; GO:1903766; P:positive regulation of potassium ion export across plasma membrane; IDA:BHF-UCL.
DR GO; GO:0006457; P:protein folding; IDA:CAFA.
DR GO; GO:0007168; P:receptor guanylyl cyclase signaling pathway; IDA:UniProtKB.
DR GO; GO:0060372; P:regulation of atrial cardiac muscle cell membrane repolarization; IMP:BHF-UCL.
DR GO; GO:0008217; P:regulation of blood pressure; IDA:UniProtKB.
DR GO; GO:1902514; P:regulation of calcium ion transmembrane transport via high voltage-gated calcium channel; ISS:BHF-UCL.
DR GO; GO:1901841; P:regulation of high voltage-gated calcium channel activity; ISS:BHF-UCL.
DR GO; GO:0035994; P:response to muscle stretch; TAS:BHF-UCL.
DR GO; GO:0036376; P:sodium ion export across plasma membrane; IEA:Ensembl.
DR GO; GO:0042311; P:vasodilation; IEA:UniProtKB-KW.
DR DisProt; DP00747; -.
DR InterPro; IPR000663; Natr_peptide.
DR InterPro; IPR030480; Natr_peptide_CS.
DR InterPro; IPR002407; Natriuretic_peptide_atrial.
DR Pfam; PF00212; ANP; 1.
DR PRINTS; PR00711; ANATPEPTIDE.
DR PRINTS; PR00710; NATPEPTIDES.
DR SMART; SM00183; NAT_PEP; 1.
DR PROSITE; PS00263; NATRIURETIC_PEPTIDE; 1.
PE 1: Evidence at protein level;
KW 3D-structure; Atrial fibrillation; Cardiomyopathy; Cell projection;
KW Direct protein sequencing; Disease variant; Disulfide bond; Hormone;
KW Phosphoprotein; Reference proteome; Secreted; Signal; Vasoactive;
KW Vasodilator.
FT SIGNAL 1..25
FT /evidence="ECO:0000250|UniProtKB:P24259"
FT CHAIN 26..151
FT /note="Natriuretic peptides A"
FT /evidence="ECO:0000269|PubMed:3838202"
FT /id="PRO_0000449721"
FT PEPTIDE 26..55
FT /note="Long-acting natriuretic peptide"
FT /evidence="ECO:0000305|PubMed:7955907,
FT ECO:0000305|PubMed:7984506, ECO:0000305|PubMed:8087923"
FT /id="PRO_0000449722"
FT PEPTIDE 56..92
FT /note="Vessel dilator"
FT /evidence="ECO:0000305|PubMed:7955907,
FT ECO:0000305|PubMed:7984506, ECO:0000305|PubMed:8087923"
FT /id="PRO_0000449723"
FT PROPEP 93..103
FT /evidence="ECO:0000305"
FT /id="PRO_0000449724"
FT PEPTIDE 104..123
FT /note="Kaliuretic peptide"
FT /evidence="ECO:0000305|PubMed:7720651,
FT ECO:0000305|PubMed:7984506, ECO:0000305|PubMed:8087923"
FT /id="PRO_0000449725"
FT PEPTIDE 119..151
FT /note="Auriculin-C"
FT /evidence="ECO:0000250|UniProtKB:P01161"
FT /id="PRO_0000449726"
FT PEPTIDE 120..151
FT /note="Urodilatin"
FT /evidence="ECO:0000269|PubMed:2972874"
FT /id="PRO_0000449727"
FT PEPTIDE 121..145
FT /note="Auriculin-D"
FT /evidence="ECO:0000250|UniProtKB:P01161"
FT /id="PRO_0000449728"
FT PEPTIDE 124..151
FT /note="Atrial natriuretic peptide"
FT /evidence="ECO:0000269|PubMed:10880574,
FT ECO:0000269|PubMed:1826098, ECO:0000269|PubMed:3838202,
FT ECO:0000269|PubMed:6230082"
FT /id="PRO_0000449729"
FT PEPTIDE 127..151
FT /note="Auriculin-B"
FT /evidence="ECO:0000250|UniProtKB:P01161"
FT /id="PRO_0000449730"
FT PEPTIDE 127..150
FT /note="Auriculin-A"
FT /evidence="ECO:0000250|UniProtKB:P01161"
FT /id="PRO_0000449731"
FT PEPTIDE 128..151
FT /note="Atriopeptin-3"
FT /evidence="ECO:0000250|UniProtKB:P01161"
FT /id="PRO_0000449732"
FT PEPTIDE 128..150
FT /note="Atriopeptin-2"
FT /evidence="ECO:0000250|UniProtKB:P01161"
FT /id="PRO_0000449733"
FT PEPTIDE 128..148
FT /note="Atriopeptin-1"
FT /evidence="ECO:0000250|UniProtKB:P01161"
FT /id="PRO_0000449734"
FT REGION 62..105
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT REGION 147..151
FT /note="Important for degradation of atrial natriuretic
FT peptide by IDE"
FT /evidence="ECO:0000269|PubMed:21098034"
FT SITE 123..124
FT /note="Cleavage; by CORIN"
FT /evidence="ECO:0000269|PubMed:10880574"
FT SITE 130..131
FT /note="Cleavage; by MME"
FT /evidence="ECO:0000269|PubMed:2972276"
FT MOD_RES 129
FT /note="Phosphoserine"
FT /evidence="ECO:0000269|PubMed:2528951"
FT DISULFID 130..146
FT /evidence="ECO:0000269|PubMed:16870210,
FT ECO:0000269|PubMed:3838202"
FT VARIANT 32
FT /note="V -> M (in dbSNP:rs5063)"
FT /id="VAR_014579"
FT VARIANT 150
FT /note="R -> Q (in ATRST2; dbSNP:rs202102042)"
FT /evidence="ECO:0000269|PubMed:23275345"
FT /id="VAR_071307"
FT VARIANT 151
FT /note="Y -> YRR"
FT /evidence="ECO:0000269|PubMed:16875975,
FT ECO:0000269|PubMed:6238331"
FT /id="VAR_082651"
FT MUTAGEN 123
FT /note="R->G: Loss of cleavage by CORIN."
FT /evidence="ECO:0000269|PubMed:10880574"
FT MUTAGEN 124..129
FT /note="Missing: No effect on degradation of atrial
FT natriuretic peptide by IDE."
FT /evidence="ECO:0000269|PubMed:21098034"
FT MUTAGEN 124..126
FT /note="Missing: Reduced degradation of atrial natriuretic
FT peptide by IDE; when associated with N-147--151-Y DEL."
FT /evidence="ECO:0000269|PubMed:21098034"
FT MUTAGEN 147..151
FT /note="Missing: Reduced degradation of atrial natriuretic
FT peptide by IDE; when associated with S-124--126-R DEL."
FT /evidence="ECO:0000269|PubMed:21098034"
FT CONFLICT 65
FT /note="E -> D (in Ref. 6; AAA35529)"
FT /evidence="ECO:0000305"
FT STRAND 129..133
FT /evidence="ECO:0007829|PDB:7BRH"
FT STRAND 139..141
FT /evidence="ECO:0007829|PDB:1YK0"
FT STRAND 144..146
FT /evidence="ECO:0007829|PDB:7BRH"
SQ SEQUENCE 151 AA; 16396 MW; F3AA066A73EC97EF CRC64;
MSSFSTTTVS FLLLLAFQLL GQTRANPMYN AVSNADLMDF KNLLDHLEEK MPLEDEVVPP
QVLSEPNEEA GAALSPLPEV PPWTGEVSPA QRDGGALGRG PWDSSDRSAL LKSKLRALLT
APRSLRRSSC FGGRMDRIGA QSGLGCNSFR Y
